INCY today
$122.27+$1.97 (+1.64%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourBullish
15 minBullish
5 minConsolidating
Daily trend turns up above $132.60
Key levels
Resistance$128.72
Resistance$123.96
Support$119.60
Support$115.00
Latest news & SEC filings
DealNatera and Incyte to collaborate on Phase II colorectal cancer study
DealNatera and Incyte agree to collaborate on mid-stage colorectal cancer trial
AnalystLeerink Partners keeps Outperform rating on Incyte, cuts price target to $150
All INCY news →About Incyte
Incyte is a biopharmaceutical company that discovers, develops, and commercializes medicines. Its portfolio spans hematology, oncology, and inflammation and autoimmunity, with drugs such as JAKAFI, ICLUSIG, MONJUVI, NIKTIMVO, PEMAZYRE, OPZELURA, and ZYNYZ. It sells through specialty pharmacies and wholesalers, and operates in the United States, Europe, Japan, and Canada.
Based on the company's 10-K filed Feb 10, 2026.
Nasdaq · Healthcare
INCYTE CORP (INCY)
What Is the Price Target for INCY?
SEPT Low Target
$108.00
SEPT Mid Target
$137.00
SEPT High Target
$157.00
Analyst Consensus
$137.00
Is INCY a Buy or Sell Right Now?
Thesis
- •Revenue growing 21.2% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for INCY.
Start Free Trial →Is INCY Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$154.62
40
Moat Score
NARROW
7/9
Piotroski Score
10.0
Altman Z-Score
What Is Smart Money Doing with INCY?
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
BUYING
1 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Stein Steven H | officer | Buy | 8,539 | $586K | Nov 6, 2026 |
| Stein Steven H | officer | Buy | 12,335 | $891K | Nov 6, 2026 |
| Stein Steven H | officer | Buy | 16,428 | $1.3M | Nov 6, 2026 |
| Stein Steven H | officer | Buy | 15,054 | $1.1M | Nov 6, 2026 |
| Stein Steven H | officer | Buy | 23,526 | $1.8M | Nov 6, 2026 |
| Stein Steven H | officer | Buy | 18,331 | $1.1M | Nov 6, 2026 |
| Stein Steven H | officer | Buy | 19,749 | $1.2M | Nov 6, 2026 |
| Stein Steven H | officer | Buy | 12,305 | $791K | Nov 6, 2026 |
| Stein Steven H | officer | Buy | 6,907 | $471K | Nov 6, 2026 |
| Stein Steven H | officer | Buy | 12,743 | $1.2M | Nov 6, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →INCY Growth Story
Revenue YoY
21.2%
3yr Revenue CAGR
14.8%
EPS Growth YoY
4173.33%
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
Dark Pool Trades for INCY
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for INCY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:28:25 | $122.27 | 2,646 | $$324K | BUY |
| 21:06:57 | $122.27 | 43,524 | $$5.3M | BUY |
| 21:00:37 | $122.27 | 1,200 | $$147K | BUY |
| 21:00:36 | $122.27 | 1,227 | $$150K | BUY |
| 21:00:36 | $122.27 | 1,562 | $$191K | BUY |
5 dark pool trades shown · $$6.1M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for INCY
PREVIEWSEPT Investing provides real-time options flow tracking for INCY, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $125 | Dec 18 | 37 | $$1000 | 2 | SWEEP |
| CALL | $125 | Dec 18 | 37 | $$500 | 1 | SWEEP |
| CALL | $125 | Dec 18 | 37 | $$500 | 1 | SWEEP |
| CALL | $125 | Dec 18 | 37 | $$1000 | 2 | SWEEP |
| CALL | $125 | Dec 18 | 37 | $$500 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About INCY
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for INCY. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$INCY officer Stein Steven H sold 22,336 shares at $117.14, a $2.62M Form 4 filed Tue Nov 10.
Join 3,500+ traders discussing INCY in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for INCYTE CORP (INCY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (6 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →INCY — frequently asked questions
What is INCY stock price today?
INCYTE CORP (INCY) is at $122.27, up 1.64% (+$1.97) at the Nov 11, 2026 close.
Why is INCY stock moving today?
Latest INCY news — Nov 10, 2026: Natera and Incyte to collaborate on Phase II colorectal cancer study · Nov 10, 2026: Natera and Incyte agree to collaborate on mid-stage colorectal cancer trial
What is the INCY price target?
The average analyst price target for INCY is $137.00, ranging from $108 to $157, based on 19 analysts. Latest: Leerink Partners maintains on Nov 5, 2026.
What do analysts rate INCY?
Analyst ratings for INCY: 4 Buy, 40 Hold, 0 Sell — consensus Hold.
Did INCY beat earnings?
INCY last reported on Oct 29, 2026: EPS -$3.60 vs -$3.93 expected — a beat of 8.4%.
What is INCY's P/E ratio?
INCY trades at a P/E of 65.3 vs a Healthcare average of 18.5.
Does INCY pay a dividend?
INCY does not currently pay a dividend.
What are INCY support and resistance levels?
Support: $119.60, $115.00, $107.78. Resistance: $123.96, $128.72, $133.11.
What are insiders doing with INCY?
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
What is the latest news on INCY?
Nov 10, 2026: Natera and Incyte to collaborate on Phase II colorectal cancer study · Nov 10, 2026: Natera and Incyte agree to collaborate on mid-stage colorectal cancer trial · Nov 5, 2026: Leerink Partners keeps Outperform rating on Incyte, cuts price target to $150